$8.05
-0.42 (-4.96%)
Open$8.49
Previous Close$8.47
Day High$8.65
Day Low$7.97
52W High$9.08
52W Low$4.52
Volume—
Avg Volume24.4K
Market Cap80.02M
P/E Ratio—
EPS$-0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-47.0% upside
Current
$8.05
$8.05
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.44M | 26.66M | 25.83M |
| Net Income | -1,145,102 | -902,602 | 1.23M |
| Profit Margin | -3.8% | -3.6% | 4.8% |
| EBITDA | 2.22M | 1.85M | 1.46M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +14.2% | +14.2% | +0.8% |
| Debt/Equity | 0.34 | 0.34 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |